Gensera Biotech Solutions Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 23-10-2024
- Paid Up Capital ₹ 0.10 M
as on 23-10-2024
- Company Age 5 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 509.23%
(FY 2023)
- Profit -546.05%
(FY 2023)
- Ebitda -886.88%
(FY 2023)
- Net Worth 71.49%
(FY 2023)
- Total Assets 59.77%
(FY 2023)
About Gensera Biotech Solutions
The Corporate was formerly known as Sudarshan Biotech Solutions Private Limited. The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Velmurugan Balasubramanian, Vasanthi Palanivel, and Shrinivas Rangachari serve as directors at the Company.
- CIN/LLPIN
U74999TN2019PTC131403
- Company No.
131403
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
31 Aug 2019
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Gensera Biotech Solutions?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Velmurugan Balasubramanian  | Director | 31-Aug-2019 | Current |
| Vasanthi Palanivel | Director | 20-Apr-2021 | Current |
| Shrinivas Rangachari | Director | 31-Aug-2019 | Current |
Financial Performance of Gensera Biotech Solutions.
Gensera Biotech Solutions Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 509.23% increase. The company also saw a substantial fall in profitability, with a 546.05% decrease in profit. The company's net worth Soared by an impressive increase of 71.49%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Gensera Biotech Solutions?
In 2023, Gensera Biotech Solutions had a public holding of 24.22%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Seragen Biotherapeutics Private LimitedActive 6 years 6 monthsVelmurugan Balasubramanian, Vasanthi Palanivel and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Gensera Biotech Solutions?
Unlock and access historical data on people associated with Gensera Biotech Solutions, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Gensera Biotech Solutions, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Gensera Biotech Solutions's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
